الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
The aim of the current study was to assess whether dexmedetomidine has extra advantage over midazolam as regards intraoperative and postoperative analgesia with minimal adverse effects. This clinical prospective clinical trial was performed on a total of 105 children (1-6 years of both genders) who were undergone herniorraphy at Children hospital, Faculty of medicine Mansoura University with the period from January 2021 to January 2022. Control group; receiving 0.2% of bupivacaine (1 mg/kg), - BM group; receiving 0.2% of bupivacaine (1 mg/kg) and midazolam 0.05 mg/kg and BD group; receiving 0.2% of bupivacaine (1 mg/kg) and Dexmedetomidine 0.5 mic/kg. TNo significant differences were recorded among the three studied groups with regard all demographic characteristics as well as regarding all hemodynamic parameters. •BD group and BM group were associated with a significant increase in FLACC compared to control group. •BD group was associated with a highly significant increase in Ramsay scale compared to BM group and control group. In addition, there was a highly significant increase in Ramsay scale in BM group compared to control group. •BD group was associated with a significant increase in the time to first analgesic request and a significant decrease in total analgesic doses compared to BM group and control group. •There was a statistically significant increase in the time to first analgesic request and a significant decrease in total analgesic doses in BM group compared to control group. •No statistically significant differences were recorded among the three studied group regarding PONV. In the context of caudal analgesia, adding dexmedetomidine or midazolam combined with bupivacaine significantly prolonged the analgesic duration, however dexmedetomidine was superior over midazolam with regard to analgesic profile without an increase in adverse effects in children undergoing lower abdominal surgery